Concinnity Genetics, a promising health tech spinout based in Edinburgh, successfully raised £3m in funding.
- The company, founded in 2023, focuses on developing breakthrough gene therapies with reliable control systems.
- The recent funding round was led by Eos Advisory, highlighting belief in Concinnity’s innovative approach.
- Key investors include Scottish Enterprise and Old College Capital, the University of Edinburgh’s venture fund.
- Concinnity’s advancing technology blends synthetic biology with AI, gaining recognition as a potential game changer in gene therapy.
Edinburgh’s health tech sphere is abuzz with the recent success of Concinnity Genetics, a newly established spinout that has made waves by securing a significant £3m in its funding round. Founded in 2023, the company is dedicated to innovating in the field of gene therapy, aiming to enhance safety and efficacy with novel control mechanisms. Leading the venture is CEO and co-founder Jessica Birt, who expresses a strong aspiration for Concinnity to become a leader in gene control applications. She remarked, “Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible.”
The funding round received substantial participation from several influential investors, led by Eos Advisory. This investment firm’s focus on groundbreaking Scottish science has found a match in Concinnity’s cutting-edge mission. Andrew McNeill, managing partner at Eos, praised the company, noting that its technology, which combines synthetic biology and AI, could be the ‘holy grail’ for emerging gene therapies—making them more effective and safer.
Accompanying Eos Advisory in this investment effort is the support from Scottish Enterprise and Old College Capital, the internal venture investment wing of the University of Edinburgh. Maven Capital Partners also contributed to this promising enterprise. This strategic alliance of investors underscores the confidence placed in Concinnity’s potential to contribute significantly to advanced therapeutics.
The University of Edinburgh, with its strong background in engineering biology, continues to act as a catalyst for innovative solutions in healthcare and related fields. Dr Andrea Taylor, representing Edinburgh Innovations, highlighted the impact that sophisticated gene control systems can have on future health paradigms. She suggests that these advances enable the creation of new treatment modalities that could radically alter the therapeutic landscape.
Concinnity Genetics stands poised to transform gene therapy safety and efficacy, supported by robust funding and innovative technology.
